ArticleFrontiers in transplantation2025
Case Report: Successful treatment of steroid-refractory graft-vs.-host disease following bilateral lung transplantation.
Article in Frontiers in transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft-vs.-host disease (GVHD) is a rare but potentially fatal complication following solid organ transplantation (SOT), with limited reported cases and high mortality rates after lung transplantation. We present a case of steroid-refractory GVHD (SR-GVHD) following bilateral lung transplantation and review the literature on GVHD in SOT. A patient developed SR-GVHD affecting the skin, gut, liver, and bone marrow following bilateral lung transplantation. Initial treatment with high-dose corticosteroids was ineffective. Subsequent therapy with rabbit anti-thymocyte globulin (rATG) and ruxolitinib led to complete remission over two months. Short tandem repeat (STR) analysis aided in diagnosis and monitoring. This case highlights the importance of early diagnosis and aggressive treatment of GVHD following SOT. We propose a treatment algorithm including rapid escalation to multi-agent immunosuppression for SR-GVHD. Interdisciplinary collaboration between solid organ and stem cell transplant specialists is crucial. Further research is needed to identify optimal strategies for prevention and treatment of GVHD in SOT recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.